These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29753391)

  • 1. [Attractiveness of France for international clinical research: 8th survey conducted by Leem (French association for pharmaceutical companies)].
    Galaup A; Barthélémy P; Pouletty-Lefebvre B; Béhier JM; Zetlaoui J; Borel T
    Therapie; 2018 Oct; 73(5):367-376. PubMed ID: 29753391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Attractiveness of France for international clinical trials in 2012: 6(th) survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Barthélémy P; Plétan Y; Courcier S
    Therapie; 2013; 68(1):1-18. PubMed ID: 23484655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [France, an attractive country for international clinical research: 2010 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Behier JM; Pletan Y; Courcier S
    Therapie; 2011; 66(1):1-15. PubMed ID: 21466772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [France, an attractive country for international clinical research: 2008 survey assessed by Leem (French association of pharmaceutical companies)].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S;
    Therapie; 2008; 63(5):345-57. PubMed ID: 19154705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. France's competitiveness in global pharmaceutical research: The situation is improving.
    d'Andon A; Galaup A; Fabron C; Detournay B; Borel T
    Therapie; 2021; 76(6):549-557. PubMed ID: 34053732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A survey on the position of France in international clinical research as assessed by pharmaceutical laboratories].
    Courcier-Duplantier S; Bouhours P; Pinton P; Sibenaler C; Lassale C;
    Therapie; 2004; 59(6):629-38. PubMed ID: 15789827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The attractive position of France in international clinical research: 2006 survey assessed by Leem (French pharmaceutical companies)].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C;
    Therapie; 2006; 61(5):407-18. PubMed ID: 17243270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Lassale C; Sibenaler C; Béhier JM; Plétan Y; Courcier S
    Therapie; 2008; 63(5):345-57. PubMed ID: 27392656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Courcier S; Sibenaler C; Couderc M; Trinquet F; Plétan Y; Lassale C; le Groupe de Travail Attractivité de la France du Leem
    Therapie; 2006; 61(5):407-18. PubMed ID: 27392823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Attractiveness of France for clinical trials: evaluation of laboratories and promoters].
    d'Enfert J; Lassale C; Prod'homme P
    Therapie; 2003; 58(3):283-9. PubMed ID: 14655322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early results from a multi-component French public-private partnership initiative to improve participation in clinical research - CeNGEPS: a prospective before-after study.
    Bordet R; Lang M; Dieu C; Billon N; Duffet JP
    BMC Med Res Methodol; 2015 Aug; 15():67. PubMed ID: 26286263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conduct of clinical trials for medicinal products in europe in the light of the European clinical trials directive. Review of regulatory and practical aspects in the different countries.
    Dubray C; Maillere P; Spriet A;
    Therapie; 2007; 62(3):193-7, 199-202. PubMed ID: 17803885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Difficulties with conducting clinical trials in France].
    Zannad F; Plétan Y
    Therapie; 2001; 56(4):341-7. PubMed ID: 11677850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [State of unmet medical needs in France in 2006: necessity of reinforcing research effort].
    Jouan-Flahault C; Billon N; Castaigne A; Henry YD; Omnes C; Puech A; Rosilio M; Lassale C
    Therapie; 2007; 62(5):393-415. PubMed ID: 18206102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The investment of pharmaceutical industry in hospital clinical research: an estimate for france in 2010].
    Fagnani F
    Therapie; 2012; 67(2):89-96. PubMed ID: 22850096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A proposal for reforming psychologists' training in France and in the European Union].
    Bouchard JP
    Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.